logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Juan Manuel Sepúlveda-Sánchez

hospital san chinarro
H指数:40
被引数:7,910

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations

更正：恶性胶质脑瘤复发后的管理：治疗策略、证据与局限性、姑息治疗、临终镇静以及终末期考虑

Clinical and Translational Oncology
IF2.5
2026-06-300
PRE
Eva María Corrales-García; Pedro David Delgado-López; Juan Manuel Sepúlveda Sánchez; Roberto Garcia Leal; Gonzalo Lendínez-Sánchez; Santiago Cabezas-Camarero; María Sánchez-Isac; María Hernández Miguel; Ana María Ruiz Moreno; José Antonio Carrillo Santos; Jerónimo González Bernal
Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations

恶性胶质脑肿瘤复发后的管理：治疗策略、证据与局限性、姑息治疗、终末期镇静以及临终考量

Clinical and Translational Oncology
IF2.5
2026-06-060
PRE
Eva María Corrales-García; Pedro David Delgado-López; Juan Manuel Sepúlveda Sánchez; Roberto Garcia Leal; Gonzalo Lendínez-Sánchez; Santiago Cabezas-Camarero; María Sánchez-Isac; Hernández Hernández Miguel; Ana Ruiz Ruiz Moreno; José Antonio Carrillo Santos; Jerónimo González Bernal
Patient-derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones

患者来源的手术样本揭示胶质母细胞瘤在特定放射学区域浸润的细胞和分子特征

Brain Pathology
IF6.2
2026-05-050
OAAI
Olaya de Dios; Juan Romero; María de los Ángeles Ramírez-González; Beatriz Herranz; Alicia Avis-Bodas; Juliana Manosalva; Diego Megías; Ana Ramos; Juan Manuel Sepúlveda-Sánchez; Ricardo Gargini; Berta Segura-Collar; Gabriel Velilla; Bárbara Meléndez; Pedro González; Luis Jiménez-Roldán; Guillermo García-Posadas; Aurelio Hernández-Laín; Ángel Pérez-Núñez; Pilar Sánchez-Gómez
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial

基于L-RNA适配体的CXCL12抑制联合放射治疗和贝伐珠单抗在 newly-diagnosed glioblastoma 中的研究：扩展I/II期GLORIA试验

Nature Communications
IF15.7
2026-04-080
OA
Frank A. Giordano; Julian P. Layer; Roberta Turiello; Lea L. Friker; Oriol Mirallas; Barbara E. F. Pregler; Anna-Laura Potthoff; Thomas Zeyen; Johannes Weller; Elena Sperk; Katharina Sahm; Christoph Oster; Sied Kebir; Peter Hambsch; Niklas Schäfer; Sebastian Kadzik; Mirjam Renovanz; Torsten Pietsch; Sotirios Bisdas; Juan Manuel Sepúlveda-Sánchez; Diego Gómez-Puerto; Maria Vieito; Michael Platten; Eleni Gkika; Oliver M. Grauer; Ghazaleh Tabatabai; Matthias Schneider; Martin Glas; Clemens Seidel; Ulrich Herrlinger; Michael Hölzel
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

与接受vorasidenib或安慰剂治疗的Grade 2，异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者中，体素（3D）评估相较于传统双向（2D）评估在INDIGO III期试验中的比较

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES

随机临床试验的初步结果：在初次治疗失败后的胶质母细胞瘤患者中比较鲁比西丁与洛莫司汀：数据分析与未来可能性

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Kashraw, Mustafa; Dunbar, Erin; Aiken, Robert; Ducray, Francois; Manrique, Teresa Garcia; Hernandez, Ainhoa; Muriel, Carolina; Piccioni, David; Sepulveda-Sanchez, Juan Manuel; Sherman, Wendy; Simonelli, Matteo; Salgado, Maria Angeles Vaz; Muzyczenko, Zena; Picker, Don; Silberman, Sandra
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

体积肿瘤生长率（TGR）建模预测了在INDIGO三期试验中，接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者的临床结局。

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

Vorasidenib在IDH1突变或IDH2突变低级别胶质瘤（INDIGO）：一项随机、双盲、安慰剂对照、III期试验的次要和探索性终点

The Lancet Oncology
IF0
2025-10-290
PRE
Timothy F Cloughesy; Martin J van den Bent; Mehdi Touat; Deborah T Blumenthal; Katherine B Peters; Benjamin M Ellingson; Jennifer L Clarke; Joe Mendez; Shlomit Yust-Katz; Liam Welsh; Warren P Mason; Francois Ducray; Yoshie Umemura; Burt Nabors; Matthias Holdhoff; Andreas F Hottinger; Yoshiki Arakawa; Juan M Sepulveda; Wolfgang Wick; Riccardo Soffietti; James Perry; Pierre Giglio; Macarena de la Fuente; Elizabeth Maher; Andrew Bottomley; Adriana E Tron; Denise Yi; Dan Zhao; Shuchi S Pandya; Lori Steelman; Islam Hassan; Patrick Y Wen; Ingo K Mellinghoff
A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209

一项关于佩米加替尼治疗经治胶质母细胞瘤或其他携带激活性FGFR1-3变异的胶质瘤的II期研究：FIGHT-209的最终结果

NEURO-ONCOLOGY
IF13.4
2025-10-010
OAAI
Franceschi, E.; van den Bent, M.; Sanson, M.; Lassman, A. B.; Lombardi, G.; Gomez, D.; Strowd, R. E.; Sepulveda Sanchez, J. M.; McBain, C.; Welsh, L.; Lobbous, M.; Dahlrot, R.; Pineda, E.; Larrieu, D.; Pellerino, A.; Narita, Y.; Bagley, S.; Oliveira, N.; Guo, Y.; Veronese, L.; Viviers, L.; Yogendran, L.; Ahluwalia, M. S.
EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL

早期肿瘤体积变化预测Midh1/2胶质瘤的临床结局：INDIGO III期试验的事后分析结果

NEURO-ONCOLOGY
IF13.4
2025-10-010
OAAI
Ellingson, B. M.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Welsh, L.; Mason, W. P.; Ducray, F.; Umemura, Y.; Nabors, B.; Holdhoff, M.; Hottinger, A. F.; Arakawa, Y.; Sepulveda, J. M.; Wick, W.; Soffietti, R.; Perry, J.; Giglio, P.; de la Fuente, M.; Maher, E.; Zhao, D.; Pandya, S. S.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.
EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB

来自INDIGO研究第3阶段的探索性分析表明，在VORASIDENIB治疗下，通过肿瘤体积减小可能存在控制癫痫发作的潜在机制。

NEURO-ONCOLOGY
IF13.4
2025-10-010
OA
Wick, W.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Welsh, L.; Mason, W. P.; Hottinger, A. F.; Sepulveda, J. M.; Soffietti, R.; Zhao, D.; Yi, D.; Weidl, D.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.
A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.

一项全球性III期、开放标签、随机对照研究，针对新诊断的MGMT未甲基化胶质母细胞瘤，比较Niraparib与标准护理替莫唑胺治疗。

NEURO-ONCOLOGY
IF13.4
2025-10-010
OAAI
Sanai, N.; Mehta, S.; Tien, A.; Tovmasyan, A.; Harmon, J.; Kennedy, W. R.; Aziez, A.; Chalmers, A.; Khasraw, M.; Lim Fat, M.; Minniti, G.; Sepulveda, J. M.; Touat, M.; Umemura, Y.
Prognostic value of 1D, 2D, and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: Radiological post-hoc analysis of the EORTC-BTG-1320 trial

1D、2D和容积肿瘤尺寸增加对WHO分级2级和3级复发脑膜瘤的预后价值：EORTC-BTG-1320试验的放射学事后分析

NEURO-ONCOLOGY ADVANCES
IF4.1
2025-01-010
OAAI
Furtner, Julia; Berchtold, Luzia; Le Rhun, Emilie; Silvani, Antonio; Ruda, Roberta; Lombardi, Giuseppe; Sepulveda-Sanchez, Juan Manuel; Brandal, Petter; Bendszus, Martin; Golfinopoulos, Vassilis; Gorlia, Thierry; Sahm, Felix; Wick, Wolfgang; Minniti, Giuseppe; Weller, Michael; Koenig, Franz; Preusser, Matthias
S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture

S100A蛋白显示出与胶质母细胞瘤微环境结构相关的炎症空间分布。

THERANOSTICS
IF13.3
2025-01-011
PRE
Comitre-Mariano, Blanca; Segura-Collar, Berta; Vellila-Alonso, Gabriel; Contreras, Ruben; Henandez-Lain, Aurelio; Valiente, Manuel; Sepulveda, Juan M.; Marcus, Stephen Garrett; Garcia-Posada, Guillermo; Jimenez-Roldan, Luis; Perez-Nunez, Angel; Gargini, Ricardo
A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS
NEURO-ONCOLOGY
IF13.4
2024-11-110
PRE
Mellinghoff, Ingo K.; van den Bent, Martin J.; Touat, Mehdi; Blumenthal, Deborah T.; Peters, Katherine B.; Ellingson, Benjamin M.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James R.; Giglio, Pierre; de la Fuente, Macarena; Maher, Elizabeth A.; Tron, Adriana E.; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial

阿泽利龙（azeliragon，一种RAGE抑制剂）与替莫唑胺和放疗联合用于新诊断胶质母细胞瘤患者的早期经验：CAN-201 NDG Ib/II期试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Pineda, E.; Sepulveda, J. M.; Valiente, M.; Vaz-Salgado, M. A.; Martinez-Garcia, M.; Ruiz Vico, M.; Velilla, G.; Mazariegos-Rubi, M. A.; Valduvieco, I.; Castro-Henriques, M.; Cano, L.; Marcus, S. G.

研究方向

暂未获取到该数据
M
Martin J. van den Bent
H 指数:128论文数:1,362被引数:10.0万
M
María Ángeles Vaz Salgado
H 指数:14论文数:140被引数:1,146
C
Carmen Balañá
H 指数:37论文数:281被引数:1.0万
P
Pilar Sánchez‐Gómez
H 指数:35论文数:180被引数:7,525
A
Aurelio Hernández‐Laín
H 指数:25论文数:210被引数:2,522
W
Wolfgang Wick
H 指数:142论文数:1,641被引数:9.5万
Á
Ángel Pérez‐Núñez
H 指数:23论文数:147被引数:1,551
R
Ricardo Gargini
H 指数:26论文数:126被引数:1.0万
M
Michael Weller
H 指数:175论文数:2,843被引数:16.5万
M
Maria Martinez‐García
H 指数:33论文数:243被引数:3,793